You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華神科技(000790.SZ)2019年度淨利潤升97.73%至6163.23萬元 擬10派0.1元
格隆匯 04-16 17:30

格隆匯4月16日丨華神科技(000790.SZ)發佈2019年年度報告,實現營業總收入7.45億元,同比增長17.67%;歸屬於上市公司股東的淨利潤6163.23萬元,同比增長97.73%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤6067.71萬元,同比增長114.67%;基本每股收益0.10元,擬每10股派發現金紅利0.1元(含税)。

報告期及去年同期銷售額佔公司同期主營業務收入10%以上的主要藥品:

1.原國家二類中藥新藥三七通舒膠囊,具有活血化瘀,活絡通脈,改善腦梗塞、腦缺血功能障礙,恢復缺血性腦代謝異常,抗血小板聚集,防止血栓形成,改善微循環,降低全血粘度,增強頸動脈血流量,主要用於心腦血管栓塞性病症,主治中風、半身不遂、口舌歪斜、言語蹇澀、偏身麻木等;擁有一種三七三醇皂苷組合物及其製備方法和用途的國內和歐洲專利,發明專利起止時間為2004-2024年,所屬註冊分類為中藥,不屬於中藥保護品種;

2.伏立康唑片,是一種廣譜的三唑類抗真菌藥,主要用於治療侵襲性麴黴病;氟康唑耐藥的念珠菌引起的嚴重侵襲性感染(包括克柔念珠菌);足放線病菌屬和鐮刀菌屬引起的嚴重感染等。伏立康唑片主要用於治療免疫缺陷患者中進行性的、可能威脅生命的感染;所屬註冊分類為化藥;

3.鼻淵舒口服液,具有疏風清熱,祛濕通竅,用於鼻炎、鼻竇炎屬肺經風熱及膽腑鬱熱證者;擁有發明專利——一種中藥組合物及其製備方法,發明專利起止時間為200561-2025531日,所屬註冊分類為中藥,不屬於中藥保護品種。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account